Imatinib

Common brands: Imatinib Mesylate, Imatinib Mesylate 400 Mg, Sprycel, Dasatinib, Phyrago

Top reporter: Mylan Pharmaceuticals Inc.

Kinase Inhibitor [EPC]Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Nucleoside Metabolic Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
17,162
Total Reports
9,026
Serious Reports
3,043
Death Reports
30
Reported Reactions
Death Report Ratio: High (17.73%)

Patient Demographics

Male
7,764
Female
6,666

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Imatinib.

# Reaction Reports % of Total
1 DRUG INEFFECTIVE 1,578
8.2%
2 DRUG RESISTANCE 1,037
5.4%
3 DEATH 1,023
5.3%
4 NAUSEA 999
5.2%
5 DIARRHOEA 998
5.2%
6 DRUG INTOLERANCE 884
4.6%
7 FATIGUE 798
4.1%
8 MALIGNANT NEOPLASM PROGRESSION 797
4.1%
9 OFF LABEL USE 721
3.7%
10 VOMITING 680
3.5%
11 DYSPNOEA 648
3.4%
12 DISEASE PROGRESSION 625
3.2%
13 PLEURAL EFFUSION 545
2.8%
14 PYREXIA 537
2.8%
15 ABDOMINAL PAIN 508
2.6%
16 ASTHENIA 507
2.6%
17 HEADACHE 504
2.6%
18 DRUG INTERACTION 496
2.6%
19 ANAEMIA 492
2.6%
20 RASH 489
2.5%
21 THROMBOCYTOPENIA 489
2.5%
22 ARTHRALGIA 482
2.5%
23 CHRONIC MYELOID LEUKAEMIA 478
2.5%
24 MYALGIA 443
2.3%
25 PRODUCT USE IN UNAPPROVED INDICATION 442
2.3%
26 PRURITUS 436
2.3%
27 TREATMENT FAILURE 426
2.2%
28 SEPSIS 418
2.2%
29 NEUTROPENIA 408
2.1%
30 MALAISE 404
2.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.